靶向GPC3的CAR-T细胞治疗肝癌研究进展

Research progress of CAR-T cells targeting GPC3 in the treatment of liver cancer

摘要: 嵌合抗原受体T细胞（CAR-T）是治疗肿瘤的新型免疫疗法，磷脂酰肌醇蛋白聚糖3（GPC3）在肝癌（HCC）组织中高表达，是治疗HCC的理想靶标，靶向GPC3的CAT-T细胞治疗HCC效果显著，被认为是最具潜力的免疫疗法之一。本文对靶向GPC3 CAR-T细胞治疗HCC的最新研究进展进行综述。

Abstract: The chimeric antigen receptor T cell(CAR-T)is a new type of immunotherapy method for treating tumors.Glypican-3(GPC3)is highly expressed in hepatocellular carcinoma(HCC)tissue, and has become an ideal target for treating HCC.CAT-T cells targeting GPC3 have significant positive effects on HCC, which is considered one of the most promising immunotherapy.This article reviews the latest research progress in CAR-T cells targeting GPC3 therapy for HCC.